Corona Remedies (NSE:CORONA) Notes Receivable: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CORONA Corona Remedies Ltd NSE:CORONA
18 GF Score
Price ₹2,098.80
! 3 Warning Signs
View Full Analysis

What is Corona Remedies Notes Receivable?

Corona Remedies NSE:CORONA +0.37% 18 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Corona Remedies's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Corona Remedies Notes Receivable Related Terms

Corona Remedies Notes Receivable Historical Data

* Premium members only.

The historical data trend for Corona Remedies's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corona Remedies Notes Receivable Chart

Corona Remedies Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Notes Receivable
0.00 0.00 0.00 0.00

Corona Remedies Quarterly Data
Mar23 Mar24 Dec24 Mar25 Jun25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:CORONA
18GF Score
Corona Remedies Ltd NSE:CORONA
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corona Remedies Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Corona Remedies (NSE:CORONA) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Corona Remedies and its competitors.
Is Corona Remedies' Notes Receivable too high?
Corona Remedies' current Notes Receivable is ₹0 Mil. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Notes Receivable compare to LLY and JNJ?
Corona Remedies' Notes Receivable of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Corona Remedies and its competitors. Corona Remedies's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current Notes Receivable of ₹0 Mil. The current Notes Receivable is ₹0 Mil. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corona Remedies Business Description

Other Exchanges 544644:India
Address S. G. Highway, CORONA House, C - Mondeal Business Park, Near Gurudwara, Thaltej, Ahmedabad, GJ, IND, 380 059
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score

Get the complete analysis for NSE:CORONA

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,098.80
Price